AstraZeneca and MSD's Lynparza is the first PARP inhibitor to demonstrate a benefit in pancreatic cancer, having hit targets in the Phase III POLO trial.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.